Nanoscale particles for lung delivery of siRNA

Journal of Drug Delivery Science and Technology

Volumn 22, Issue 1, 2012, Pages 99-108

  Nascimento, T L ^a   Hillaireau, H ^a   Fattal, E ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Lipoplexes; Lung; Nanoparticles; Polyplexes; Small interfering RNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CALCIUM PHOSPHATE; CHITOSAN; CIGARETTE SMOKE; DOUBLE STRANDED RNA; HYALURONIC ACID; LIPOSOME; LUNG SURFACTANT; MACROGOL; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NANOPARTICLE; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

AEROSOL; BIOCOMPATIBILITY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CIGARETTE SMOKING; COMPETITIVE INHIBITION; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRY POWDER; ENVIRONMENTAL EXPOSURE; HYDROPHILICITY; IMMUNOGENICITY; INHALATION; LIPOSOMAL DELIVERY; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG RESISTANCE; NANOENCAPSULATION; NEBULIZATION; NONHUMAN; OSMOTIC PRESSURE; PARTICULATE MATTER; POLYMERIZATION; PROTEIN TARGETING; REVIEW; RISK REDUCTION; RNA BINDING; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; RNA SYNTHESIS;

EID: 84857405522     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(12)50010-9     Document Type: Review

References (149)

1. Devi G.R. - siRNA-based approaches in cancer therapy. - Cancer Gene Ther., 13, 819-829, 2006.
2. Aagaard L., Rossi J.J. - RNAi therapeutics: principles, prospects and challenges. - Adv. Drug Deliv Rev., 59, 75-86, 2007. (Pubitemid 46770900)
3. Fattal E., Bochot A. - State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. - Int. J. Pharm., 364, 237-248, 2008.
4. Fattal E., Barratt G. - Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. - Br. J. Pharm., 157, 179-194, 2009.
5. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. - Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. - Nature, 391, 806-811, 1998. (Pubitemid 28099681)
6. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. - Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. - Nature, 411, 494-498, 2001. (Pubitemid 32494397)
7. Vaucheret H., Fagard M. - Transcriptional gene silencing in plants: targets, inducers and regulators. - Trends Genet., 17, 29-35, 2001. (Pubitemid 32332977)
8. Kennerdell J.R., Yamaguchi S., Carthew R.W. - RNAi is activated during Drosophila oocyte maturation in a manner dependent on aubergine and spindle-E. - Genes Dev., 16, 1884-1889, 2002. (Pubitemid 34832918)
9. Timmons L., Fire A. - Specific interference by ingested dsRNA. - Nature, 395, 854, 1998.
10. Ketting R.F., Fischer S.E., Bernstein E., Sijen T., Hannon G.J., Plasterk R.H. - Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. - Genes Dev., 15, 2654-2659, 2001. (Pubitemid 32988876)
11. Hannon G.J., Rossi J.J. - Unlocking the potential of the human genome with RNA interference. - Nature, 431, 371-378, 2004. (Pubitemid 39265678)
12. Meister G., Tuschl T. - Mechanisms of gene silencing by double-stranded RNA. - Nature, 431, 343-349, 2004. (Pubitemid 39265674)
13. Nykanen A., Haley B., Zamore P.D. - ATP requirements and small interfering RNA structure in the RNA interference pathway. - Cell, 107, 309-321, 2001. (Pubitemid 33049975)
14. Martinez J., Patkaniowska A., Urlaub H., Lührmann R., Tuschl T. - Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. - Cell, 110, 565-574, 2002.
15. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. - RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. - Cell, 101, 25-33, 2000.
16. Leung R.K., Whittaker P.A. - RNA interference: from gene silencing to gene-specific therapeutics. - Pharmacol. Ther., 107, 222-239, 2005. (Pubitemid 40910042)
17. Lee R.C., Feinbaum R.L., Ambras V. - The C. elegans heterochrony gene lin-4 encodes small RNAs with antisense complementarity to lin-14. - Cell, 75, 843-854, 1993. (Pubitemid 24014542)
18. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., Zamore RD. - A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. - Science, 293, 834-838, 2001. (Pubitemid 32743968)
19. Jana S., Chakraborty C., Nandi S., Deb J.K. - RNA interference: potential therapeutic targets. - Appl. Microbiol. Biotechnol., 65, 649-657, 2004. (Pubitemid 39506545)
20. Sontheimer E.J., Carthew R.W. - Silence from within: endogenous siRNAs and miRNAs. - Cell, 122, 9-12, 2005. (Pubitemid 40977934)
21. Chu C., Rana T.M. - Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. - PLoS Biol., 4, e210, 2006.
22. de Fougerolles A., Novobrantseva T. - siRNA and the lung: research tool or therapeutic drug? - Curr. Opin. Pharmacol., 8, 280-285, 2008.
23. Koshkina N.V., Agoulnik I.Y., Melton S.L., Densmore C.L., Knight V. - Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. - Molecular Therapy, 8, 249-254, 2003. (Pubitemid 37062835)
24. Sham J.O.H., Zhang Y., Finlay W.H., Roa W.H., Lobenberg R. - Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. - Int. J. Pharm., 269, 457-467, 2004. (Pubitemid 38045308)
25. Zou Y., Tornos C., Qiu X., Lia M., Perez-Soler R. - p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. - Clinical Cancer Res., 13, 4900-4908, 2007. (Pubitemid 47294798)
26. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. - Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. - Nature, 432, 173-178, 2004. (Pubitemid 39545841)
27. Dykxhoorn D.M., Lieberman J. - Knocking down disease with siRNAs. - Cell, 126, 231-235, 2006.
28. Knowles M.R., Hohneker K.W., Zhou Z., Olsen J.C., Noah T.L., Hu P.C., Leigh M.W., Engelhardt J.F., Edwards L.J., Jones K.R., Grossman M., Wilson J.M., Johnson L.G., Boucher R.C. - A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. - N. Engl. J. Med., 333, 823-831, 1995.
29. Cone R.A. - Barrier properties of mucus. - Adv. Drug Del. Rev., 61, 75-85, 2009.
30. Quraishi M.S., Jones N.S., Mason J. - The rheology of nasal mucus: a review. - Clin. Otolaryngol. Allied Sci., 23, 403-413, 1998.
31. Samet J.M., Cheng P.W. - The role of airway mucus in pulmonary toxicology. - Environ. Health Perspect., 102, Suppl. 2, 89-103, 1994. (Pubitemid 24217798)
32. Evans C.M., Koo J.S. - Airway mucus: the good, the bad, the sticky. - Pharmacol. Ther., 121, 332-348, 2009.
33. Jany B., Gallup M., Tsuda T., Basbaum C. - Mucin gene expression in rat airways following infection and irritation. - Biochem. Biophys. Res. Commun., 181, 1-8, 1991.
34. Ling S.H., van Eeden S.F. - Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. - Int. J. Chronic Obstructive Pulmonary Disease, 4, 233-243, 2009.
35. Ahn M.H., Kang C.M., Park C.S., Park S.J., Rhim T., Yoon P.O., Chang H.S., Kim S.H., Kyono H., Kim K.C. -Titanium dioxide particle-induced goblet cell hyperplasia: association with mast cells and IL-13. - Respiratory Research, 6, 34, 2005.
36. Haswell L.E., Hewitt K., Thome D., Richter A., Gaca M.D. - Cigarette smoke total particulate matter increases mucous secreting cell numbers in vitro: a potential model of goblet cell hyperplasia. - Toxicol In vitro, 24, 981-987, 2010.
37. Yang W., Peters J.I., Williams R.O., 3rd - Inhaled nanoparticles, a current review. - Int. J. Pharm., 356, 239-247, 2008.
38. Suarez S., Hickey A.J. - Drug properties affecting aerosol behavior. - Respir. Care, 45, 652-666, 2000. (Pubitemid 30484805)
39. Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. - Trojan particles: large porous carriers of nanoparticles for drug delivery. - Proc. Natl. Acad. Sci. USA, 99, 12001-12005, 2002.
40. Sakagami M. - In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. - Adv. Drug Deliv. Rev., 58, 1030-1060, 2006. (Pubitemid 44712023)
41. Patton J.S., Byron P.R. - Inhaling medicines: delivering drugs to the body through the lungs. - Nat. Rev. Drug Discov., 6, 67-74, 2007. (Pubitemid 46020287)
42. Byron P.R. - Prediction of drug residence times in regions of the human respiratory-tract following aerosol inhalation. - J. Pharm. Sci., 75, 433-438, 1986. (Pubitemid 16083635)
43. Heyder J., Rudolf G. - Mathematical-models of particle deposition in the human respiratory-tract. - J. Aerosol. Sci., 15, 697-707, 1984. (Pubitemid 15437588)
44. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W. - Deposition of particles in the human respiratory-tract in the size range 0.005-16-Mu-M. - J. Aerosol. Sci., 17, 811-825, 1986. (Pubitemid 17492310)
45. Gilmore I.R., Fox S.P., Hollins A.J., Akhtar S. - Delivery strategies for siRNA-mediated gene silencing. - Curr. Drug Deliv., 3, 147-145, 2006.
46. Li W., Szoka F.C., Jr. - Lipid-based nanoparticles for nucleic acid delivery. - Pharm. Res., 24, 438-449, 2007. (Pubitemid 46295166)
47. Fattal E., Delattre J., Dubernet C., Couvreur P. - Liposomes for the delivery of nucleotides and oligonucleotides. - STP Pharma Sci., 9, 383-390, 1999.
48. Han S.E., Kang H., Shim G.Y., Suh M.S., Kim S.J., Kim J.S., Oh Y.K. - Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. - Int. J. Pharm., 2007.
49. De Rosa G., De Stefano D., Laguardia V., Arpicco S., Simeon V., Carnuccio R., Fattal E. - Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages. - Eur. J. Pharm. Biopharm., 70, 7-18, 2008.
50. Plank C., Mechtler K., Szoka F.C., Jr., Wagner E. - Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. - Hum. Gene Ther., 7, 1437-1446, 1996. (Pubitemid 26293564)
51. Lambert G., Fattal E., Brehier A., Feger J., Couvreur P. - Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. - Biochimie, 80, 969-976, 1998.
52. Lavigne C., Thierry A.R. - Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells. - Biochimie, 89, 1245-1251, 2007. (Pubitemid 47505271)
53. De Oliveira M.C., Fattal E., Couvreur P., Lesieur P., Bourgaux C., Ollivon M., Dubernet C. - pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. - Biochim. Biophys. Acta, 1372, 301-310, 1998. (Pubitemid 28451553)
54. Fattal E., Couvreur P., Dubernet C. - "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. - Adv. Drug Deliv. Rev., 56, 931-946, 2004. (Pubitemid 38520202)
55. Cardoso A., Trabulo S., Moreira J.N., Duzgunes N., de Lima M.C. - Targeted lipoplexes for siRNA delivery. - Methods Enzymol., 465, 267-287, 2009.
56. Gautam A., Waldrep J.C., Densmore C.L. - Aerosol gene therapy. - Mol. Biotechnol., 23, 51-60, 2003.
57. Toulany M., Minjgee M., Kehlbach R., Chen J., Baumann M., Rodemann H.P. - ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. - Radiother. Oncol., 97, 338-345, 2010.
58. Han S.W., Roman J. - Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. - Oncogene, 25, 4341-4349, 2006. (Pubitemid 44100504)
59. Ma X., Xu D., Ai Y., Ming G., Zhao S. - Fas inhibition attenuates lipopolysaccharide-induced apoptosis and cytokine release of rat type II alveolar epithelial cells. - Mol. Biol. Rep., 37, 3051-3056, 2010.
60. Nicolazzi C., Mignet N., de la Figuera N., Cadet M., Ibad R.T., Seguin J., Scherman D., Bessodes M. - Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. - J. Control. Release, 88, 429-443, 2003. (Pubitemid 36335802)
61. Bally M.B., Harvie P., Wong F.M., Kong S., Wasan E.K., Reimer D.L. - Biological barriers to cellular delivery of lipid-based DNA carriers. - Adv. Drug Deliv. Rev., 38, 291-315, 1999. (Pubitemid 29376579)
62. Shi F., Wasungu L., Nomden A., Stuart M.C., Polushkin E., Engberts J.B., Hoekstra D. - Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. - Biochem J., 366, 333-341, 2002. (Pubitemid 34971834)
63. Surace C., Arpicco S., Dufay-Wojcicki A., Marsaud V., Bouclier C., Clay D., Cattel L., Renoir J.M., Fattal E. - Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. - Molecular Pharmaceutics, 6, 1062-1073, 2009.
64. Taetz S., Bochot A., Surace C., Arpicco S., Renoir J.M., Schaefer U.F., Marsaud V., Kerdine-Roemer S., Lehr C.M., Fattal E. - Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. - Oligonucleotides, 19, 103-115, 2009.
65. Bastow E.R., Byers S., Golub S.B., Clarkin C.E., Pitsillides A.A., Fosang A.J. - Hyaluronan synthesis and degradation in cartilage and bone. - Cell. Mol. Life Sci., 65, 395-413, 2008. (Pubitemid 351214652)
66. Turley E.A. - Extracellular matrix remodeling: multiple paradigms in vascular disease. - Circ. Res., 88, 2-4, 2001. (Pubitemid 32064073)
67. Jothy S. - CD44 and its partners in metastasis. - Clin. Exp. Metastasis, 20, 195-201, 2003.
68. Ponta H., Sherman L., Herrlich P.A. - CD44: from adhesion molecules to signalling regulators. - Nat. Rev. Mol. Cell Biol., 4, 33-45, 2003. (Pubitemid 36077255)
69. Santos A.O., da Silva L.C., Bimbo L.M., de Lima M.C., Simoes S., Moreira J.N. - Design of peptide-targeted liposomes containing nucleic acids. - Biochim. Biophys. Acta, 1798, 433-441, 2010.
70. Clive S., Webb D.J., MacLellan A., Young A., Byrne B., Robson L., Smyth J.F., Jodrell D.I. - Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. - Clin. Cancer Res., 7, 3071-3078, 2001. (Pubitemid 32963826)
71. Chen Y., Sen J., Bathula S.R., Yang Q., Fittipaldi R., Huang L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. - Mol. Pharm., 6, 696-705, 2009.
72. Li S.D., Huang L. - Surface-modified LPD nanoparticles for tumor targeting. - Ann NY Acad. Sci., 1082, 1-8, 2006.
73. Li S.D., Chen Y.C., Hackett M.J., Huang L. - Tumor-targeted delivery of siRNA by self-assembled nanoparticles. - Mol. Ther., 16, 163-169, 2008.
74. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. - Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. - Proc. Natl. Acad. Sci. USA, 107, 10737-10742, 2010.
75. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., Reimer D.C., Pozharov V.P., Minko T. - Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. - Pharm. Res., 26, 382-394, 2009.
76. Griesenbach U., Kitson C., Escudero Garcia S., Farley R., Singh C., Somerton L., Painter H., Smith R.L., Gill D.R., Hyde S.C., Chow Y.H., Hu J., Gray M., Edbrooke M., Ogilvie V., MacGregor G., Scheule R.K., Cheng S.H., Caplen N J., Alton E.W. - Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. - Respir. Res., 7, 26, 2006.
77. Wang J.C., Lai S., Guo X., Zhang X., de Crombrugghe B., Sonnylal S., Arnett F.C., Zhou X. - Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. - Arthritis Res. Ther., 12, R60, 2010.
78. Tompkins S.M., Lo C.Y., Tumpey T.M., Epstein S.L. - Protection against lethal influenza virus challenge by RNA interference in vivo. - Proc. Natl. Acad. Sci. USA, 101, 8682-8686, 2004. (Pubitemid 38745831)
79. Bitko V., Musiyenko A., Shulyayeva O., Barik S. - Inhibition of respiratory viruses by nasally administered siRNA. - Nat. Med., 11, 50-55, 2005. (Pubitemid 40215837)
80. Li B.J., Tang Q., Cheng D., Qin C., Xie F.Y., Wei Q., Xu J., Liu Y., Zheng B.J., Woodle M.C., Zhong N., Lu P.Y. - Using siRNA in prophylactic and therapeutic regimens against SARS Coronavirus in Rhesus macaque. - Nat. Med., 11, 944-951, 2005. (Pubitemid 41294439)
81. Massaro D., Massaro G.D., Clerch L.B. - Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. - Am. J. Physiol. Lung Cell Mol. Physiol., 287, L1066-1070, 2004. (Pubitemid 39391038)
82. Gutbier B., Kube S.M., Reppe K., Santel A., Lange C., Kaufmann J., Suttorp N., Witzenrath M. - RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. - Pulm. Pharmacol. Ther., 23, 334-344, 2010.
83. Toub N., Malvy C., Fattal E., Couvreur P. - Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. - Biomed. Pharmacother., 60, 607-620, 2006. (Pubitemid 44635092)
84. Fattal E., Bochot A. - Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. - Adv. Drug Deliv. Rev., 58, 1203-1223, 2006.
85. Reischl D., Zimmer A. - Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. - Nanomedicine, 5, 8-20, 2009.
86. Beck-Broichsitter M., Gauss J., Packhaeuser C.B., Lahnstein K., Schmehl T., Seeger W., Kissel T., Gessler T. - Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. - Int. J. Pharm., 367, 169-178, 2009.
87. Rytting E., Nguyen J., Wang X., Kissel T. - Biodegradable polymeric nanocarriers for pulmonary drug delivery. - Expert Opin. Drug Deliv., 5, 629-639, 2008. (Pubitemid 351998253)
88. Schurch S., Gehr P., Im Hof V., Geiser M., Green F. - Surfactant displaces particles toward the epithelium in airways and alveoli. - Respir. Physiol., 80, 17-32, 1990. (Pubitemid 20160258)
89. Fattal E., Vauthier C., Aynie I., Nakada Y., Lambert G., Malvy C., Couvreur P. - Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. - J. Control. Release, 53, 137-143, 1998. (Pubitemid 28218697)
90. Gomes dos Santos A.L., Bochot A., Tsapis N., Artzner F., Bejjani R.A., Thillaye-Goldenberg B., de Kozak Y., Fattal E., Behar-Cohen F. - Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. - Pharm. Res., 23, 770-781, 2006.
91. Behr J.P. - The proton sponge: a trick to enter cells the viruses did not exploit. - Chimia, 51, 34-36, 1997.
92. Boussif O., Zanta M.A., Behr J.P. - Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. - Gene Ther., 3, 1074-1080, 1996. (Pubitemid 27036110)
93. Zuber G., Dauty E., Nothisen M., Belguise P., Behr J.P. - Towards synthetic viruses. - Adv. Drug Deliv. Rev., 52, 245-253, 2001.
94. Akinc A., Thomas M., Klibanov A.M., Langer R. - Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. - J. Gene Med., 7, 657-663, 2005. (Pubitemid 40744532)
95. Werth S., Urban-Klein B., Dai L., Hobel S., Grzelinski M., Bakowsky U., Czubayko F., Aigner A. - A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. - J. Control. Release, 112, 257-270, 2006.
96. Godbey W.T., Mikos A.G. - Recent progress in gene delivery using non-viral transfer complexes. - J. Control. Release, 72, 115-125, 2001. (Pubitemid 32522349)
97. Vinogradov S.V., Bronich TK., Kabanov A.V. - Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. - Bioconjug. Chem., 9, 805-812, 1998. (Pubitemid 28542249)
98. Petersen H., Fechner P., Fischer D., Kissel T. - Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers. - Macromolecules, 35, 6867-6874, 2002. (Pubitemid 34991102)
99. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. - RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. - Gene Ther., 12, 461-466, 2005. (Pubitemid 40394299)
100. Malek A., Merkel O., Fink L., Czubayko F., Kissel T., Aigner A. - In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. - Toxicol. Appl. Pharmacol., 236, 97-108, 2009.
101. Kuruba R., Wilson A., Gao X., Li S. - Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation. - AAPS J., 11, 23-30, 2009.
102. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. - A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. - Pharm. Res., 16, 1273-1279, 1999. (Pubitemid 29393618)
103. Beyerle A., Hobel S., Czubayko F., Schulz H., Kissel T., Aigner A., Stoeger T. - In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. - Toxicol. In vitro, 23, 500-508, 2009.
104. Thomas M., Lu J.J., Ge Q., Zhang C., Chen J., Klibanov A.M. - Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. - Proc. Natl. Acad. Sci. USA, 102, 5679-5684, 2005. (Pubitemid 40559619)
105. Lin S.Y., Lin F.S., Chen M.K., Tsai L.R., Jao Y.C., Lin H.Y., Wang C.L., Hwu Y.K., Yang C.S. - One-pot synthesis of linear-like and photoluminescent polyethylenimines for intracellular imaging and siRNA delivery. - Chem. Commun. (Camb)., 46, 5554-5556, 2010.
106. Jere D., Xu C.X., Arote R., Yun C.H., Cho M.H., Cho C.S. - Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. - Biomaterials, 29, 2535-2547, 2008.
107. Jere D., Jiang H.L., Kim Y.K., Arote R., Choi Y.J., Yun C.H., Cho M.H., Cho C.S. - Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. - Int. J. Pharm., 378, 194-200, 2009.
108. Brognard J., Clark A.S., Ni Y., Dennis P.A. - Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. - Cancer Res., 61, 3986-3997, 2001. (Pubitemid 32720961)
109. Xu C.X., Jere D, Jin H., Chang S.H., Chung Y.S., Shin J.Y., Kim J.E., Park S.J., Lee Y.H., Chae C.H., Lee K.H., Beck G.R., Jr., Cho C.S., Cho M.H. - Poly(esteramine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. - Am. J. Respir. Crit. Care Med., 178, 60-73, 2008. (Pubitemid 351919194)
110. Bolcato-Bellemin A.L., Bonnet M.E., Creusat G., Erbacher P., Behr J.P. - Sticky overhangs enhance siRNA-mediated gene silencing. - Proc. Natl. Acad. Sci. USA, 104, 16050-16055, 2007. (Pubitemid 350099361)
111. Kleemann E., Neu M., Jekel N., Fink L., Schmehl T., Gessler T., Seeger W., Kissel T. - Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. - J. Control. Release, 109, 299-316, 2005. (Pubitemid 41737272)
112. Park M.R., Han K.O., Han I.K., Cho M.H., Nah J.W., Choi Y.J., Cho C.S. - Degradable polyethylenimine-alt-poly(ethylene glycol) copolymers as novel gene carriers. - J. Control. Release, 105, 367-380, 2005.
113. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., Kjems J. - RNA interference in vitroand in vivo using a novel chitosan/siRNA nanoparticle system. - Mol. Ther., 14, 476-484, 2006. (Pubitemid 44296092)
114. Durcan N., Murphy C., Cryan S.A. - Inhalable siRNA: potential as a therapeutic agent in the lungs. - Mol. Pharm., 5, 559-566, 2008.
115. Liu X., Howard K.A., Dong M., Andersen M.O., Rahbek U.L., Johnsen M.G., Hansen O.C., Besenbacher F., Kjems J. - The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. - Biomaterials, 28, 1280-1288, 2007. (Pubitemid 44816373)
116. Andersen M.O., Howard K.A., Paludan S.R., Besenbacher F., Kjems J. - Delivery of siRNA from lyophilized polymeric surfaces. - Biomaterials, 29, 506-512, 2008. (Pubitemid 350103802)
117. Andersen M.O., Howard K.A., Kjems J. - RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. - Methods Mol. Biol., 555, 77-86, 2009.
118. Nguyen J., Steele T.W., Merkel O., Reul R., Kissel T. - Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. - J. Control. Release, 132, 243-251, 2008.
119. Oster C.G., Wittmar M., Unger F., Barbu-Tudoran L., Schaper A.K., Kissel T. - Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. - Pharm. Res., 21, 927-931, 2004. (Pubitemid 38870140)
120. Unger F., Wittmar M., Kissel T. - Branched polyesters based on poly[vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(d,l-lactide-co-glycolide): effects of polymer structure on cytotoxicity. - Biomaterials, 28, 1610-1619, 2007. (Pubitemid 46080471)
121. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., Kissel T., Seeger W. - Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. - Toxicol. Appl. Pharmacol., 215, 100-108, 2006. (Pubitemid 44118400)
122. Varkouhi A.K., Lammers T., Schiffelers R.M., Van Steenbergen M.J., Hennink W.E., Storm G. - Gene silencing activity of siRNA polyplexes based on biodegradable polymers. - Eur. J. Pharm. Biopharm., 2011.
123. Jain R.A. - The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. - Biomaterials, 21, 2475-2490, 2000.
124. Cartiera M.S., Johnson K.M., Rajendran V., Caplan M.J., Saltzman W.M. - The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. - Biomaterials, 30, 2790-2798, 2009.
125. Nie H., Ho M.L., Wang C.K., Wang C.H., Fu Y.C. - BMP-2 plasmid loaded PLGA/HAp composite scaffolds for treatment of bone defects in nude mice. - Biomaterials, 30, 892-901, 2009.
126. Mura S., Hillaireau H., Nicolas J., Le Droumaguet B., Gueutin C., Zanna S., Tsapis N., Fattal E. - Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. - International Journal of Nanomedicine, (in press), 2011.
127. Manca M.I., Mourtas S., Dracopoulos V., Fadda A.M., Antimisiaris S.G. - PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. - Colloids Surf. B Biointerfaces, 62, 220-231, 2008. (Pubitemid 351274020)
128. Campolongo M.J., Luo D. - Drug delivery: old polymer learns new tracts. - Nat. Mater., 8, 447-448, 2009.
129. Cun D., Jensen D.K., Maltesen M.J., Bunker M., Whiteside P., Scurr D., Foged C., Nielsen H.M. - High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. - Eur. J. Pharm. Biopharm., 77, 26-35, 2011.
130. Walter E., Moelling K., Pavlovic J., Merkle H.P. - Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. - J. Control. Release, 61, 361-374, 1999. (Pubitemid 29413030)
131. Roy I., Mitra S., Maitra A., Mozumdar S. - Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. - Int. J. Pharm., 250, 25-33, 2003. (Pubitemid 35447934)
132. Welzel T., Radtke I., Meyer-Zaika W., Heumann R., Epple M. - Transfection of cells with custom-made calcium phosphate nanoparticles coated with DNA. - J. Mater. Chem., 14, 2213-2217, 2004.
133. Maitra A.- Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. - Expert Review of Molecular Diagnostics, 5, 893-905, 2005. (Pubitemid 41666184)
134. Sokolova V., Kovtun A., Prymak O., Meyer-Zaika W., Kubareva E.A., Romanova E.A., Oretskaya T.S., Heumann R., Epple M. - Functionalisation of calcium phosphate nanoparticles by oligonucleotides and their application for gene silencing. - J. Mater. Chem., 17, 721-727, 2006.
135. Sokolova V.V., Radtke I., Heumann R., Epple M. - Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. - Biomaterials, 27, 3147-3153, 2006. (Pubitemid 43247588)
136. Olton D., Li J., Wilson M.E., Rogers T., Close J., Huang L., Kumta P.N., Sfeir C. - Nanostructured calcium phosphates (NanoCaPs) fornon-viral gene delivery: Influence of the synthesis parameters on transfection efficiency. - Biomaterials, 28, 1267-1279, 2007. (Pubitemid 44809431)
137. Bisht S., Bhakta G., Mitra S., Maitra A. - pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. - Int. J. Pharm., 288, 157-168, 2005. (Pubitemid 39656464)
138. Li J., Chen Y.C., Tseng Y.C., Mozumdar S., Huang L. - Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. - J. Control. Release, 142, 416-421, 2010.
139. de Jonge J., Holtrop M., Wilschut J., Huckriede A. - Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. - Gene Therapy, 13, 400-411, 2005.
140. de Fougerolles A., Novobrantseva T. - siRNA and the lung: research tool or therapeutic drug? - Current Opinion in Pharmacology, 8, 280-285, 2008.
141. Lehrman S. - Virus treatment questioned after gene therapy death. - Nature, 401, 517-518, 1999.
142. Cavazzana-Calvo M., Fischer A. - Gene therapy for severe combined immunodeficiency: are we there yet? - J. Clin. Invest., 117, 1456, 2007.
143. Di Gioia S., Conese M. - Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. - Drug Design, Development and Therapy, 2, 163, 2008.
144. Zallen D. - US gene therapy in crisis. - Trends in Genetics, 16, 272-275, 2000.
145. De Rosa G., Quaglia F., La Rotonda M.I., Appel M., Alphandary H., Fattal E. - Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. - J. Pharm. Sci., 91, 790-799, 2002. (Pubitemid 34639643)
146. De Rosa G., Bochot A., Quaglia F., Besnard M., Fattal E. - A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. - Int. J. Pharm., 254, 89-93, 2003. (Pubitemid 36259817)
147. De Rosa G., Quaglia F., Bochot A., Ungaro F., Fattal E. - Long-term release and improved intracellular penetration of oligonucleotide- polyethylenimine complexes entrapped in biodegradable microspheres. - Biomacromolecules, 4, 529-536, 2003. (Pubitemid 36701221)
148. Gomes dos Santos A.I., Bochot A., Doyle A., Tsapis N., Siepmann J., Siepmann F., Schmaler J., Besnard M., Behar-Cohen F., Fattal E. - Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta2 oligonucleotide improves the outcome of glaucoma surgery. - J. Control. Release, 112, 369-381, 2006. (Pubitemid 43737146)
149. Gomez-Gaete C., Fattal E., Silva L., Besnard M., Tsapis N. - Dexamethasone acetate encapsulation into Trajan particles. - J. Control. Release, 128, 41-49, 2008.